Genomic profiling can help personalize cancer care, but patients may not be offered these tests due to a burdensome ...

Tempus AI is expanding its clinical oncology offering with the launch of ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer. ・The tool combines digital pathology and genomic ...

The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

For Josh Henderson, 66, of Olympia, getting genetic testing was a no-brainer. “The first time I came to Fred Hutch, my oncologist suggested it,” said the retired IT manager who received a metastatic ...

We retrospectively reviewed prostate cancer consults within one health care system from November 2, 2021, to January 2, 2023. We compared the proportion of patients who received genomic testing in the ...

Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ...

Impact of a diagnostic bronchoscopy service with embedded reflex molecular testing within an oncology centre in patients with lung cancer: The Bronchiomics study. This is an ASCO Meeting Abstract from ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment. A recent ...

Prostate cancer is one of the top diagnoses for men with cancer, but early stages are tough to detect. “You know, maybe some ...

A major review of nearly 800,000 men has found prostate cancer screening using a specific test is likely to reduce deaths ...